GC Cell affiliate BioCentriq raises $29 mn in funding

[Courtesy of BioCentriq]

South Korean biotechnology company GC Cell Corp. announced on Thursday that its affiliate, BioCentriq, successfully secured a total of $29.2 million in funding via its series A funding round held in January 2024.

BioCentriq plans to use the funds for the development and enhancement of cell therapy treatments, facility upgrades for production, technological investments, and the recruitment of global experts. The sponsors involved in the fundraising were not disclosed.

“Our investors’ confidence in BioCentriq’s vision and capabilities is reflected in this successful fundraising,” James Park, who was appointed as interim chief executive officer of BioCentriq on January 1, 2024, said. “This financing will enable us to continue to innovate in the field of cell therapy development and bring innovative treatments to our partners and patients around the world.”